In conclusion, our results suggest that the simultaneous inhibition of all PIM kinases could be an efficient therapeutic strategy in those PTCL with PIM upregulation. The gene discussed is PIM1; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.